Insights & news

Belgium - Belgian Competition Authority Offers Guidance on Mergers of Local Hospital Networks

  • 23/07/2020
  • Articles

On 22 July 2020, the Belgian Competition Authority (BCA) published a note (the Note) which discusses the application of the Belgian merger control rules to the creation of local hospital networks (locoregionale ziekenhuisnetwerken; réseaux hospitaliers locorégionaux – see the attached Note and press release in different language versions).
 
The Note was prompted by various requests from the sector where hospitals may now be required by the Law of 28 February 2019 “modifying the consolidated law of 10 July 2018 regarding hospitals and other institutions of care, as regards the clinical networking between hospitals” (the Law) to establish a local network of hospitals. It explains that the creation of such a network may give rise to a concentration that is notifiable under the Belgian merger control rules (the Note does not mention the possible application of the European merger control rules). This will depend on whether there is a change of control on a lasting basis over at least some of the hospitals involved in the transaction and whether the financial turnover-related thresholds are reached. This double assessment will be made on a case-by-case basis.
 
The Note offers extensive guidance on the concept of change of control against the specific background of the Law and will be welcomed by stakeholders. This is because, as the Note points out, the Law and the merger control rules pursue different goals and are not always easy to reconcile. More broadly, unlike the situation in neighbouring countries such as The Netherlands, the sector is still coming to grips with the application of the competition rules. Merger control is only one aspect of a wider category of rules which also includes such bodies of law as the public procurement procedures and the anti-cartel rules. As recently as October of last year, the BCA started an investigation into alleged competition infringements that aimed to prevent biosimilar medicines from entering the market (see, Van Bael & Bellis News Alert of 8 October 2019). The procedure reportedly targeted not only pharmaceutical firms, but also specific hospitals.  

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 31/07/2020
    • Articles

    British Medical Journal Publishes Critical Review of Orphan Medicines Rules Ahead of Release of European Commission's Own Studies

    As part of the preparatory work for its Pharmaceutical Strategy for Europe which is due in the fourth quarter of 2020, the European Commission (the Commission) is expected to publish shortly an external study and own work assessing the regulatory framework governing orphan medicines and the paediatric rules.

    Read more
    • 28/07/2020
    • Articles

    US President Signs Executive Order Implementing International Pricing Index Model

    On 24 July 2020 the US President signed four executive orders designed to lower medicine prices in the United States (see, attached press release). One of these orders, which has not yet been made publicly available, implements a form of international reference pricing and “take[s] action to ensure that the Medicare program and seniors pay no more for [a series of costly medicines] than any economically comparable OECD country, ending foreign countries’ free loading off the backs of American taxpayers and pharmaceutical investments” (the “International Pricing Index Model” or “IPI Model”).

    Read more
    • 20/07/2020
    • Articles

    Belgium - Constitutional Court Rejects Request for Suspension of Key Provisions of Latest Medicine Shortages Law

    On 16 July 2020, the Constitutional Court rejected several requests for suspension of Articles 2, 3 and 4 of the Law of 20 December 2019 modifying various laws to tackle medicine shortages (Wet van 20 december 2019 tot wijziging van diverse wetgevingen wat de tekorten aan geneesmiddelen betreft/Loi du 20 décembre 2020 modifiant diverses législations, en ce qui concerne les pénuries de medicaments – the Law – see attachments). The requests had been introduced by the Belgian Association of Parallel Importers and Exporters, various other parties active in the parallel trade in medicines and pharmacists in the Democratic Republic of the Congo and Rwanda (the Applicants).

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *